FDA misses cannabis deadline mandated by Congress (Newsletter: February 19, 2026)
Tom Angell is the editor of Marijuana Moment. A 25-year veteran in the cannabis and drug law reform movement, he covers the policy and politics of marijuana, psychedelics and other substances. He previously reported for Forbes, Marijuana.com and MassRoots, and was given the Hunter S. Thompson Media Award by NORML and has been named […]
FDA Misses Deadline To Publish Cannabinoid List And Define Hemp ‘Containers,’ Drawing Industry Criticism
The Food and Drug Administration (FDA) has missed a congressionally mandated deadline to publish a list of known cannabinoids as federal hemp laws are set to change later this year in a way that stakeholders argue will upend the existing market. As part of appropriations legislation that President Donald Trump signed last year, many hemp […]
FDA head discusses cannabis benefits & concerns (Newsletter: February 13, 2026)
NY gov signs marijuana biz zoning fix; VA cannabis consumers’ parental rights; FL medical marijuana expansion; CO cannabis revenue outpaces alcohol Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Your support makes Marijuana Moment possible… Before […]
Alaska Government Task Force Recommends Legalizing Psychedelic Therapy Upon FDA Approval
An Alaska psychedelics task force is recommending that the state move forward with plans to provide regulated access to psychedelics if the federal Food and Drug Administration (FDA) authorizes the medical use of substances like psilocybin and MDMA. After about a year of work studying the issue under a law enacted in 2024, the Alaska […]
FDA Faces Deadline To Publish Cannabinoid Lists And Define Hemp Product ‘Containers’ Under Law Trump Signed
In about nine months, federal hemp laws are scheduled to significantly change in a way that industry stakeholders say would effectively upend the market by re-criminalizing most consumable cannabinoid products. But in the interim, the Food and Drug Administration (FDA) is facing a deadline next week to help inform future hemp policy. As part of […]